.svg){kind=small}
Sep-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
VET CBD is stocked at 273 licensed dispensaries across California, Arizona, and 4 other states, 257 of them in California, with the deepest coverage in Los Angeles, Sacramento, San Diego, San Francisco, and La Mesa. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In September 2026, VET CBD concentrated 96.08% of sales in Tincture & Sublingual, with Edible at 3.92%, a mix that tightened month over month as Tincture & Sublingual fell 11.05% MoM and Edible declined 12.57% MoM. Year over year, Tincture & Sublingual contracted 3.22% while Edible dropped 20.86%, against a brand-level sales change of -4.06% YoY and a 24‑month decline of -18.00%. Within California Tincture & Sublingual the brand held rank 4, even as the category’s average price for the brand at $48.48 sat above the brand-wide average price, which rose 2.48% YoY to $46.32. The compound of a 11.05% MoM dip in the core category and a 20.86% YoY slide in the secondary format implies tightening consumer pull toward fewer SKUs and price bands, concentrating the franchise while raising vulnerability to any further softness in Tincture & Sublingual.
These shifts imply a positioning anchored in higher-price therapeutic tinctures, given a $48.48 average in Tincture & Sublingual versus $22.12 in Edible and a maintained rank 4 in California despite -3.22% YoY category sales decline. With 96.08% share in Tincture & Sublingual and a concurrent 2.48% YoY uptick in overall average price, the brand is signaling elasticity headroom in core use-cases while ceding breadth in lower-priced formats as Edible share remains at 3.92% and contracts 12.57% MoM. The combination of a top-5 rank and double-digit MoM pullback in both categories suggests the brand’s demand is more sensitive to monthly inventory or patient-need cycles than to cross-category substitution, reinforcing a strategy to protect rank 4 in Tincture & Sublingual rather than chase growth in Edible.
Competitive Landscape
VET CBD sits at rank #4 in CA Tincture & Sublingual for September 2026, unchanged from #4 in September 2025, while its peak at #3 in July 2026 marks a 1-position improvement from the current standing; over the last three months VET CBD held #4 consistently, indicating a flat quarter-on-quarter rank trend alongside a 1-rank retreat from the category peak. Competitively, Papa & Barkley held #1 year over year and remains #1 despite a -8.4% sales YoY change, and Care By Design stayed at #3 while posting a -23.9% sales YoY change, placing VET CBD in proximity to incumbents with declining sales, whereas Mary's Medicinals climbed from #7 to #5 on +22.3% sales YoY momentum; this mix of stability at #4 and nearby volatility implies VET CBD’s flat rank masks a window to retake #3 if it converts neighboring share softness into incremental gains.
Notable Products
The steepest decline came from CBD/THC 20:1 Regular Strength Tincture (1000mg CBD, 50mg THC, 2oz, 60ml), down 26.43% while sliding to rank 5, as the 20:1 Extra Strength Pet Tincture (250mg CBD, 25mg THC, 60ml, 2oz) dropped 16.17% at rank 4; in contrast, CBD/THC 20:1 Regular Strength Tincture (250mg CBD, 12.5mg THC, 60ml, 2oz) gained 13.79% and held rank 1. Eight of the top ten SKUs are Tincture & Sublingual, yet two Edible soft chew SKUs fell 40.43% and 4.70% at ranks 7 and 8, implying the portfolio is concentrated in tinctures but vulnerable at the edges where trial formats underperformed. The 10:1 strength line split, with the 500mg tincture up 1.78% at rank 3 while the 250mg variant dropped 44.79% at rank 10 and the Unflavored 500mg fell 19.54% at rank 9, indicating consumer trade-up toward higher-strength flagship tinctures and away from lower-dose or non-flavored options. Taken together, the mix suggests VET CBD is consolidating around a few 20:1 and higher-dose 10:1 leaders while premium-size 20:1 and peripheral formats need price-pack or positioning resets to prevent further rank erosion.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
